Biomark Diagnostics Inc. (FRA:20B)

Market Cap	33.01M +83.7%
Revenue (ttm)	17.14K -82.1%
Net Income	-878.62K
EPS	-0.01
Shares Out	106.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.3200
Previous Close	0.2960
Day's Range	0.3100 - 0.3200
52-Week Range	0.1530 - 0.4200
Beta	-0.38
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Biomark Diagnostics

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 20B

Financial Performance

In fiscal year 2026, Biomark Diagnostics's revenue was 59,787, a decrease of -61.23% compared to the previous year's 154,216. Losses were -1.48 million, -23.35% less than in 2025.

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 8, 2026

Data Sources Report a data error